Esperion is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors.

Many individuals with elevated risk of heart disease are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies. Our lead product candidate, ETC-1002, is a first-in-class therapy designed to significantly lower levels of LDL-C and improve other cardiometabolic risk factors — without the side effects associated with statin use — potentially prolonging the lives and improving the health of millions of people, worldwide.